Launches
See how rival launches and data readouts are received.
Monitor competitor launches, label news, patient and HCP conversation and policy changes across public sources — with aggregated insight built for compliance-aware teams.
Lolly connects public discussion of treatments, competitors, access and policy so brand, medical and market access teams see how the landscape is changing — in aggregate.
See how rival launches and data readouts are received.
Understand experience themes across brands, in aggregate.
Follow how professionals discuss treatment options.
Track pricing, access and regulatory conversation.
Follow approvals, indication news, congress readouts and launches, and see how the conversation responds.
Compare conversation volume and themes by brand, therapy area or campaign across public sources.
See aggregated themes on access, cost, support and treatment experience across competing brands.
Understand how healthcare professionals discuss competing data, guidelines and treatment choices.
Watch pricing, reimbursement and regulatory conversation that can shift the competitive landscape.
Rival A’s label expansion drove 2.3× more conversation, led by HCP accounts on X.
Access and cost are the top patient themes this month — 41% of brand conversation.
A pricing proposal in Germany is gaining coverage across trade and policy press.
Ask Ana how competitor news is received, what patients discuss and where the access conversation is moving.
See how competitor approvals and launches are discussed by patients, HCPs and media.
Follow expert reaction to competitor data at medical congresses and in journals.
Compare aggregated experience themes on access, cost and support across brands.
Watch reimbursement, pricing and policy talk that may shift your position.
Benchmark awareness campaigns and disease-area conversation against competitors.
Spot misleading claims about your therapy area before they shape perception.
Lolly analyzes publicly available conversation and reports themes in aggregate. It is not designed to identify or profile individual patients.
Lolly is not a pharmacovigilance system. Teams can route conversations that need review into their own adverse-event process.
Source, topic and keyword filters help teams look at professional, patient and media conversation separately.
You can track brand and generic names, indications, conditions and medical terms through custom keywords and topics.
Brand, competitive intelligence, medical affairs, market access and communications teams, with findings reviewed under their own governance.
Understand competitor moves, patient themes and policy shifts across public conversation — with insight your teams can review.